Skip to main content

Table 1 Correlation between CDCA3 expression and clinical classification in OSCCs

From: Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest

   Results of immunostaining  
Clinical classification   No. patients (%)  
  Total CDCA3 negative CDCA3 positive pvalue
Age at surgery (years)     
<60 23 9 (39) 14 (61)  
60, <70 22 11 (50) 11 (50) 0.852
70 50 22 (44) 28 (56)  
Gender     
Male 58 28 (48) 30 (52) 0.317
Female 37 14 (38) 23 (62)  
T-primary tumor     
T1 6 3 (50) 3 (50) 0.020*
T2 56 30 (54) 26 (46)  
T3 15 5 (33) 10 (67)  
T4 18 4 (22) 14 (78)  
T1 + T2 62 33 (53) 29 (47) 0.015*
T3 + T4 33 9 (27) 24 (73)  
N-regional lymph node     
N (−) 56 25 (45) 31 (55) 0.919
N (+) 39 17 (44) 22 (56)  
Stage     
I 6 3 (50) 3 (50) 0.235
II 36 18 (50) 18 (50)  
III 17 8 (47) 9 (53)  
IV 36 13 (36) 23 (64)  
Histopathologic type     
Well 60 26 (43) 34 (57) 0.803
Moderately 31 14 (45) 17 (55)  
Poorly 4 2 (50) 2 (50)  
Tumor site     
Gingiva 28 9 (32) 19 (68) 0.456
Tongue 51 25 (49) 26 (51)  
Buccal mucosa 9 4 (44) 5 (56)  
Oral floor 7 4 (57) 3 (43)  
  1. *p < 0.05.